05 IDIBELLInstitut d’Investigació Biomèdica de Bellvitge (IDIBELL) is a research centre focused on cellular medicine, where high level basic research focuses on relevant clinical matters and economic development. IDIBELL is a joint research initiative set up as a legal entity in 2004 by the Bellvitge University Hospital, the Catalan Institute of Oncology, the University of Barcelona and the Institute of Imaging Diagnosis. A key aspect of IDIBELL’s research is its proximity to the patient, for location and daily clinical activity of many of its researchers. The real proximity of high standard clinicians with excellent basic researchers has made translational research a reality in IDIBELL. IDIBELL’s mission focuses on excellence in cellular medicine. Its vision is making the Bellvitge Health Area one of the great medical centres of southern Europe thanks to its combination of comprehensive medical care, research experience and unique economic environment. The fundamental objectives of IDIBELL are: (i) to advance and promote science in its main research areas –i.e. Cancer and human molecular genetics; Neurosciences; Infectious pathology and transplantation; Growth factors, hormones and diabetes, Inflammatory, chronic and degenerative diseases, as well as Cancer Epigenetics and Biology; (ii) to establish interrelations between basic and clinical research, epidemiology and healthcare services; (iii) to stimulate collaboration between IDIBELL researchers with other institutions and enterprises; and (iv) to produce and disseminate to the general public the main scientific advances. As such, IDIBELL is strongly positioned to provide excellent opportunities for its researchers well into the future. In particular, the group of New Therapies of Genes and Transplants that participates in this project belongs to the area of Infectious pathology and transplantation and conducts research on innate immunity and xenotransplantation.

In the TRANSLINK project, IDIBELL will lead and co-ordinate the work of WP3 focused on elucidating the mechanisms leading to BHV damage and related inflammatory events, as well as co-ordinate the link with WP1 for selection of materials from patients that could be used for ex-vivo experiments. IDIBELL will also collaborate with WP5 for analysis of genetically modified tissues. In particular, IDIBELL plans to assess the role of complement and the contribution of immune cells such as macrophages on BHV degeneration. The group has extensive experience studying the molecular bases of transplant rejection and assessing genetic engineering strategies to prolong graft survival of tissue and cellular xenografts.

Contributors to TRANSLINK: 

  • Dr. Cristina Costa, DVM, PhD: Principal Investigator
  • Dr. Maribel Marquina, PhD: Research Associate